Formoterol/fluticasone propionate - Ache Laboratories

Drug Profile

Formoterol/fluticasone propionate - Ache Laboratories

Latest Information Update: 24 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ache Laboratories
  • Class Antiallergics; Antiasthmatics; Ethanolamines; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Chronic obstructive pulmonary disease

Most Recent Events

  • 18 Oct 2016 Ache withdraws a phase III trial for Chronic Obstructive Pulmonary Disease prior to enrolment in Brazil (NCT01393145)
  • 15 Jul 2011 Clinical trials in Chronic obstructive pulmonary disease in Brazil (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top